I
N THE LAST six months, two important planning documents for tissue engineering and regenerative medicine have been released. One is the strategic plan prepared by the Multi-Agency Tissue Engineering Science (MATES) Interagency Working Group (IWG) and published in June 2007. Entitled ''Advancing Tissue Science and Engineering,'' the MATES IWG plan identifies strategic priorities and implementation steps for a coordinated federal effort to advance the field. It represents the collective thinking of the MATES IWG members, and the Executive Summary for this plan is published in this issue. It has the support and buy-in not only of the MATES IWG members, but also of the Office of Science and Technology Policy and the National Science and Technology Council. The other document is an article in this issue of the journal authored by Johnson et al. and entitled ''Strategic Directions in Tissue Engineering.'' This planning effort, led by four individuals active in the field and involving a number of others, used what is described as a modified Hoshin process to assess the immediate priority of fourteen different categories of critical activities, with the goal being for tissue engineering to achieve clinical success by 2021.
These two efforts are highly complementary to each other and together provide considerable direction as to what is needed in the future to advance the field. The MATES IWG plan identifies four what are called ''overarching goals'' for the field. These range from understanding the basic biology; to scaffolds and matrix; to the enabling tools that will be necessary; and finally to issues of scale-up, translation, and commercialization. It then identifies eight strategic priorities. The Hoshin process, on the other hand, provides an analysis of an interdependent set of activities, and the need for an understanding of angiogenesis, of stem cell science, and of the use of molecular biology and systems biology tools dominate the results. Also, high on the list from the Hoshin analysis are cell sourcing and characterization, clinical understanding and interaction, and immunologic understanding and control. Although angiogenesis is identified as being critical to the growing of larger, thicker engineered constructs, nothing is said about innervation, which many considered to be equally important. Furthermore, whereas the Hoshin process identifies stem cell science as important, the technologies necessary to move stem cell-based therapies to the patient bedside are not directly addressed in either planning document. Finally, although understanding basic biology is a priority in both plans, within this there is no discussion of developmental biology, a field of critical importance as one moves from the replacement to the repair and regeneration of tissues and organs.
Both plans address issues related to translation and commercialization. Knowledge generated from research in basic science and the development of enabling technologies contribute to and inform the systems and processes for translation to products and commercialization. It will be difficult, however, to prioritize the list of ''strategic priorities'' in the MATES IWG plan, because all are important and interdependent. For example, in vitro and in vivo model systems serve to elucidate a product's mechanism of action and inform the development of appropriate assessment measures to address short-and long-term patient monitoring, as well as product performance. Because the establishment of a viable industry is a goal of both plans, criteria for prioritizing ''strategic priorities'' should be developed with the at-large tissue-engineering community and with active participation of industry leaders.
Although the eventual goal is to create off-the-shelf products available on demand, for the present and foreseeable future, most, if not all, products of tissue engineering and regenerative medicine will contain living components that may not be amenable to the testing and performance criteria of conventional regulated products. As discussed at the April 2006 Food and Drug Administration (FDA) Liaison Meeting in Washington, DC, tissue-engineered products do not fit into existing regulatory paradigms, and new guidance for these products is needed, along with information on acceptable release criteria for product characterization and appropriate non-destructive test methods.
Although there has been considerable effort by U.S. and international regulatory authorities to develop regulatory approaches for tissue-engineered products, clear pathways through the regulatory process have not been completely defined. The U.S. FDA, for its part, has made considerable progress in the regulatory designation of such products, many of which are combination products, which determines the product's regulatory approval process. There is still a need, however, for more guidance and transparency in this regard, and there may be a need for a different regulatory approach, at least for some products.
Although the use of post-market surveillance strategies for approved products aid in the continuing assessment of safety and effectiveness as mentioned in the MATES IWG plan and also have been helpful in monitoring synthetic implants, there needs to be discussion of what would constitute appropriate and acceptable post-market approaches for tissueengineered products and whether certain pre-approval requirements would be amenable to such strategies, perhaps shortening the time and cost to product approval. Also, although both plans identify standards development as important for product characterization and certification, there is no mention of whether assessment of the effort has demonstrated utility to industry for scale-up and manufacturing, as an example, or their uniform acceptability to regulatory authorities.
Cost-reimbursement issues are identified in the MATES IWG plan, but not in the document by Johnson, et. al. Because low reimbursement rates can often be an impediment to product acceptance by end users in the healthcare environment, attention to cost recovery issues and their relationship to clinical and economic outcomes is equally important. According to the MATES IWG plan, there are ongoing efforts to streamline cost-reimbursement and regulatory approval processes. This will be extremely helpful to product developers and industry investors, although efforts to provide input on decision-making and transparency of the process for the at-large community would help to ensure participation in a cross-educational process between the respective agencies and industry.
A critical concern, in particular for the MATES IWG, is how the federal government can implement the road map that these plans provide. This is addressed at a certain level in the MATES IWG strategic plan, but there needs to be a more-detailed implementation plan. The MATES IWG plan describes public meetings and workshops as vehicles for providing input to the plan, with the development of resulting guidelines forming the basis of interagency implementation plans and integration of activities ensured by the MATES IWG. Although this may be a reasonable approach, efforts should be directed toward establishing a constructive dialogue with the at-large community and transparency of deliberations and outcomes.
Both plans address funding needs. Although the MATES IWG plan acknowledges that federal funding will be important in achieving the identified strategic priorities and describes possible funding options, there are no clearly defined funding strategies other than the National Institute of Biomedical Imaging and Bioengineering-led interagency funding announcement, ''Enabling Technologies for Tissue Engineering and Regenerative Medicine.'' Although this funding announcement is cited as an implementation mechanism for many of the strategic priorities, it represents only one element. Furthermore, as indicated in the MATES IWG plan, it is hoped that the plan may serve as a catalyst for bringing investigators into the field from other disciplines. Although this may be helpful, the ''best and brightest'' will only be attracted to a well-funded initiative. Thus, what is needed is a well-developed implementation and funding plan to achieve the stated goals.
When and where appropriate, transparency, crosseducation, and cooperation between all interested partners should be explored and encouraged in all aspects of implementation strategies. As part of this, an approach should be considered for sharing progress of federal efforts with the at-large community to track and provide input on redirection of efforts, as necessary. This should be part of the implementation and funding plan.
Finally, in whatever way a particular individual may disagree with the details of these two planning documents, it must be recognized that these major efforts will help to move the field forward, and those who were involved deserve the thanks of our community. These both represent platforms on which to build, and as much discovery research is yet to be done, any plan for the advancement of tissue engineering and regenerative medicine must be considered a dynamic document that will continue to evolve.
